PAK1 is a novel therapeutic target in tyrosine kinase inhibitor-resistant lung adenocarcinoma activated by the PI3K/AKT signaling regardless of EGFR mutation

De-Wei Wu, Tzu-Chin Wu, Chih-Yi Chen, Huei Lee

Research output: Contribution to journalArticlepeer-review

34 Citations (Scopus)

Fingerprint

Dive into the research topics of 'PAK1 is a novel therapeutic target in tyrosine kinase inhibitor-resistant lung adenocarcinoma activated by the PI3K/AKT signaling regardless of EGFR mutation'. Together they form a unique fingerprint.

Medicine & Life Sciences